The committee will meet to discuss the available data supporting the use of molnupiravir to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who have tested positive for COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Back to All Events
Earlier Event: November 4
Blood Products Advisory Committee
Later Event: December 2
Oncologic Drugs Advisory Committee